Adult (aged 18 or older at the time of inclusion) rheumatology or gastroenterology patients presenting a diagnosis for any of the following pathologies : Rheumatoid Arthritis (RA) Ankylosing Spondylarthritis (AS) Axial Spondyloarthritis with no signs of AS (AxSpa) Psoriatic Arthritis (PsA) Crohn's Disease (CD) Ulcerative Colitis (UC)
Stable and treated for at least 3 months prior to inclusion either with an adalimumab (ADA) biosimilar or originator adalimumab (40 mg dose injections only)
For whom the treating physician has decided to switch to Yuflyma® (40 mg / 0.4 mL) on the day of their inclusion (decision independent from the study)
Able to initiate treatment within 4 weeks of inclusion
Have an email account
Have a mobile phone number
Able to understand and complete French-language questionnaires
Are not opposed to participating in the study.
Are covered by French National Health Insurance.
Patients treated with adalimumab originator 80 mg.
Patients under curatorship or guardianship or otherwise deprived of liberty
Patients unable to understand and complete French-language questionnaires
Pregnant women or women of childbearing potential with a desire of becoming pregnant concomitant to treatment with Yuflyma®.
You may not be if
Patients younger than 18 years old at the date of inclusion
